These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38833451)

  • 1. High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors.
    Kim NK; Suh DH; Kim K; No JH; Kim YB; Kim M; Cho YH
    PLoS One; 2024; 19(6):e0304704. PubMed ID: 38833451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.
    Liu JF; Kindelberger D; Doyle C; Lowe A; Barry WT; Matulonis UA
    Gynecol Oncol; 2013 Nov; 131(2):352-6. PubMed ID: 23954902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study.
    Kim M; Suh DH; Choi JY; Bu J; Kang YT; Kim K; No JH; Kim YB; Cho YH
    Medicine (Baltimore); 2019 May; 98(20):e15354. PubMed ID: 31096435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
    Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT
    Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
    Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter
    Jin L; Zhao W; Zhang J; Chen W; Xie T; Wang L; Fan W; Xie S; Shen J; Zheng H; Hu W; Wei Q; Dong M; Wang Q; Shen J; Liu Y
    Cancer Med; 2020 Mar; 9(5):1638-1647. PubMed ID: 31908156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
    Fan T; Zhao Q; Chen JJ; Chen WT; Pearl ML
    Gynecol Oncol; 2009 Jan; 112(1):185-91. PubMed ID: 18954898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells in the differential diagnosis of adnexal masses.
    Suh DH; Kim M; Choi JY; Bu J; Kang YT; Kwon BS; Lee B; Kim K; No JH; Kim YB; Cho YH
    Oncotarget; 2017 Sep; 8(44):77195-77206. PubMed ID: 29100380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Int J Biol Markers; 2015 Nov; 30(4):e394-400. PubMed ID: 26109367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
    Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
    J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect comparison of the diagnostic performance of
    Hu X; Li D; Liang Z; Liao Y; Yang L; Wang R; Wang P; Cai J
    BMC Cancer; 2021 Oct; 21(1):1080. PubMed ID: 34615498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.